- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
Ipsen received regulatory approval for Cabometyx, marking a competitive development with Merck in the renal cell carcinoma space.
3 reports, 2 independent
Updated Aug 25
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ipsen received regulatory approval for Cabometyx, marking a competitive development with Merck in the renal cell carcinoma space.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.Also in this story
- Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.
- The FDA is reviewing TAR-200 for approval, a process involving major pharmaceutical companies like Merck, AstraZeneca, and Pfizer in the oncology space.
- Merck's product, Enflonsia, received approval from the FDA in the United States on August 28, 2025.
Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The entities involved
Coverage
Newest first; wire copies grouped- ZacksExelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now? Exelixis, Inc. (EXEL) is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commer
- ZacksExelixis Gains 15.6% YTD: How Should You Play the Stock? Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the industry’s growth of
- Business WireExelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors – Approval is based on the phase 3 CABI